Limits...
New pharmacologic perspectives in pneumology: beclomethasone-formoterol extrafine.

Paggiaro P - Open Respir Med J (2009)

Bottom Line: Combination therapy with inhaled corticosteroids (ICS) and long-acting-beta2-agonists (LABA) is recommended in a large part of asthmatic subjects (those who are not controlled with low-dose ICS alone).Recently, a new beclomethasone/formoterol combination in an extrafine HFA formulation has been developed.This new technology allows to obtain a very high fine particle fraction which reaches lower airways, while the dose which remain in the upper airways and possibly responsible for systemic side effects is very low.Therefore, this combination allows a different dose ratio between BDP and the other ICS (budesonide, fluticasone), in favour of a lower dose of BDP.

View Article: PubMed Central - PubMed

Affiliation: Cardio-Thoracic and Vascular Department, University of Pisa, Italy.

ABSTRACT
International asthma guidelines have recently focused on the concept of , which is the main outcome to reach and maintain in the long term management. Asthma control is associated with several positive consequences, both in terms of quality of life and pathophysiological findings. Combination therapy with inhaled corticosteroids (ICS) and long-acting-beta2-agonists (LABA) is recommended in a large part of asthmatic subjects (those who are not controlled with low-dose ICS alone).Recently, a new beclomethasone/formoterol combination in an extrafine HFA formulation has been developed. This new technology allows to obtain a very high fine particle fraction which reaches lower airways, while the dose which remain in the upper airways and possibly responsible for systemic side effects is very low. Therefore, this combination allows a different dose ratio between BDP and the other ICS (budesonide, fluticasone), in favour of a lower dose of BDP. Recent studies have demonstrated the equivalence of this new combination with the other ICS/LABA combination, as regards all asthma outcomes. Then, this new BDP/formoterol combination may increase the possibility to manage adequately patients with moderate-to-severe asthma.

No MeSH data available.


Related in: MedlinePlus

Dose-effect ratio, in terms of FEV1 increase, of the two different formulations of beclomethasone: the traditional CFC formulation, and the new extra-fine HFA formulation. To obtain the same effect on FEV1 of 250 mcg of BDP in the traditional formulation, only 100 mcg of BDP in the new extra-fine HFA formulation is required [11a, 11b].
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2682924&req=5

Figure 2: Dose-effect ratio, in terms of FEV1 increase, of the two different formulations of beclomethasone: the traditional CFC formulation, and the new extra-fine HFA formulation. To obtain the same effect on FEV1 of 250 mcg of BDP in the traditional formulation, only 100 mcg of BDP in the new extra-fine HFA formulation is required [11a, 11b].

Mentions: These data lead to an equivalence between BDP in the extrafine HFA formulation and BDP in the traditional CFC formulation of 1:2.5 (Fig. 2) [11]. This means that a dose of 100 mcg of BDP in extrafine HFA formulation is equivalent, in terms of efficacy, to 250 mcg of BDP in traditional CFC formulation, with a significant lower risk of systemic side effects.


New pharmacologic perspectives in pneumology: beclomethasone-formoterol extrafine.

Paggiaro P - Open Respir Med J (2009)

Dose-effect ratio, in terms of FEV1 increase, of the two different formulations of beclomethasone: the traditional CFC formulation, and the new extra-fine HFA formulation. To obtain the same effect on FEV1 of 250 mcg of BDP in the traditional formulation, only 100 mcg of BDP in the new extra-fine HFA formulation is required [11a, 11b].
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2682924&req=5

Figure 2: Dose-effect ratio, in terms of FEV1 increase, of the two different formulations of beclomethasone: the traditional CFC formulation, and the new extra-fine HFA formulation. To obtain the same effect on FEV1 of 250 mcg of BDP in the traditional formulation, only 100 mcg of BDP in the new extra-fine HFA formulation is required [11a, 11b].
Mentions: These data lead to an equivalence between BDP in the extrafine HFA formulation and BDP in the traditional CFC formulation of 1:2.5 (Fig. 2) [11]. This means that a dose of 100 mcg of BDP in extrafine HFA formulation is equivalent, in terms of efficacy, to 250 mcg of BDP in traditional CFC formulation, with a significant lower risk of systemic side effects.

Bottom Line: Combination therapy with inhaled corticosteroids (ICS) and long-acting-beta2-agonists (LABA) is recommended in a large part of asthmatic subjects (those who are not controlled with low-dose ICS alone).Recently, a new beclomethasone/formoterol combination in an extrafine HFA formulation has been developed.This new technology allows to obtain a very high fine particle fraction which reaches lower airways, while the dose which remain in the upper airways and possibly responsible for systemic side effects is very low.Therefore, this combination allows a different dose ratio between BDP and the other ICS (budesonide, fluticasone), in favour of a lower dose of BDP.

View Article: PubMed Central - PubMed

Affiliation: Cardio-Thoracic and Vascular Department, University of Pisa, Italy.

ABSTRACT
International asthma guidelines have recently focused on the concept of , which is the main outcome to reach and maintain in the long term management. Asthma control is associated with several positive consequences, both in terms of quality of life and pathophysiological findings. Combination therapy with inhaled corticosteroids (ICS) and long-acting-beta2-agonists (LABA) is recommended in a large part of asthmatic subjects (those who are not controlled with low-dose ICS alone).Recently, a new beclomethasone/formoterol combination in an extrafine HFA formulation has been developed. This new technology allows to obtain a very high fine particle fraction which reaches lower airways, while the dose which remain in the upper airways and possibly responsible for systemic side effects is very low. Therefore, this combination allows a different dose ratio between BDP and the other ICS (budesonide, fluticasone), in favour of a lower dose of BDP. Recent studies have demonstrated the equivalence of this new combination with the other ICS/LABA combination, as regards all asthma outcomes. Then, this new BDP/formoterol combination may increase the possibility to manage adequately patients with moderate-to-severe asthma.

No MeSH data available.


Related in: MedlinePlus